Bumpus Namandje 4

What Happened

• Bumpus Namandje, a director of Recursion Pharmaceuticals (RXRX), was granted 88,424 restricted stock units (RSUs) on 2026-06-17 (acquisition recorded at $0.00). The RSUs vest the earlier of June 17, 2027 or the day before the 2027 annual meeting, subject to continued service. On 2026-06-18 he sold 3,963 shares in an open-market transaction at $3.18 per share, totaling $12,602 (reported value).

Key Details

• Transaction dates and prices: 2026-06-17 grant of 88,424 RSUs @ $0.00; 2026-06-18 sale of 3,963 shares @ $3.18 (total ~$12,602).
• Shares owned after the transactions: not specified in the provided filing summary.
• Footnotes: F1 — RSUs automatically granted under the issuer’s Outside Director Compensation Policy; vesting as noted above. F2 — the 6/18 sale was made pursuant to a Rule 10b5‑1 trading plan adopted March 3, 2026.
• Filing timing: Form 4 was filed 2026-06-22. The 6/18 sale appears to be reported within the two-business-day window; the 6/17 RSU grant appears to have been reported late (filed after the two-business-day deadline).

Context

• RSU grants are an acquisition but do not convert to vested shares until the vesting condition is met; they are common director compensation and not an immediate market purchase. Sales executed under a 10b5‑1 plan are preplanned trades and are typically routine; the sale here is relatively small (~$12.6k) compared with the RSU award.